M4E(R2): The CTD – Efficacy July 2017
- Docket Number:
- Issued by:
Guidance Issuing OfficeCenter for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research
This is one in a series of guidances that provide recommendations for applicants preparing the Common Technical Document for the Registration of Pharmaceuticals for Human Use (CTD) for submission to the U.S. Food and Drug Administration (FDA or Agency). A common format for technical documentation significantly reduces the time and resources needed to compile applications for registration of human pharmaceuticals by eliminating the need for applicants to reformat data and information for submission to multiple regulatory authorities. This harmonization facilitates regulatory reviews, efficient communication between regulators and applicants, as well as the efficient exchange of information between regulatory authorities.
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2015-D-3235.